glp-1 degradation Profiles. Shown are the profiles of native (), (Pro 9 GLP-1 and GLP-2 Orchestrate Intestine

Kim and Egan (2008)

Of the two peptides only OXM was found to stimulate insulin secretion but its potency was too low to be of clinical benefit (Holst 2024

is a member of advisory boards for Novo Nordisk and gives occasional paid lectures for this and other companies

Following a thorough analysis of our previous Phase IIb data and trial design, we are confident that with the preferred modified release formulation and optimized future trial design, we can advance a competitive oral GLP-1 molecule into registration-enabling studies to meet the ongoing medical needs of people living with obesity. The ongoing open-label, randomized study is assessing the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron administered orally in healthy adults aged 18 years or older